Antithrombin-lowering in hemophilia: a closer look at fitusiran

Antithrombin-lowering in hemophilia: a closer look at fitusiran - ScienceDirect

Single‐domain antibodies targeting antithrombin reduce bleeding in hemophilic mice with or without inhibitors

A Molecular Revolution in the Treatment of Hemophilia. - Abstract - Europe PMC

Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial - The Lancet Haematology

Thrombin generation for monitoring hemostatic therapy in hemophilia A: A narrative review - Verhagen - 2022 - Journal of Thrombosis and Haemostasis - Wiley Online Library

Fitusiran update following EAHAD 2021 Congress – WFH - World Federation of Hemophilia

Fitusiran prophylaxis leads to 61% reduction in bleeds among people with hemophilia A or B

Monthly injections of fitusiran found to reduce bleeds in patients with hemophilia A and B

Fitusiran reduces bleeding events in patients with severe haemophilia - BJH

WO2021262695A1 - Methods and compositions for treating hemophilia - Google Patents